Last reviewed · How we verify
NCT05571553: TNCM
E-health and People Living With Major Neurocognitive Disorder - CARE© and ESOGER© Applications
NA trial testing Recommendations and reorientation towards healthcare resources in Major Neurocognitive Disorder in 115 participants. Completed in 29 September 2023.
29 September 2023
Quick facts
| Lead sponsor | Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 115 |
| Start date | 1 December 2022 |
| Primary completion | 29 September 2023 |
| Estimated completion | 29 September 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Recommendations and reorientation towards healthcare resources
Conditions studied
- Major Neurocognitive Disorder — all drugs for Major Neurocognitive Disorder →
- Frailty — all drugs for Frailty →
Sponsor
Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Who can join
65 and older, any sex, with Major Neurocognitive Disorder or Frailty. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The care pathways of people living with major neurocognitive disorders (MNCD) are often inadequate due to poor access to resources, long delays, and resources that are poorly adapted to expectations and needs. This situation was exacerbated during the coronavirus disease (COVID-19) pandemic due to the reduction of available resources and care provider burnout. People living with MNCD are at risk of becoming more fragile, which can lead to emergency room visits and hospitalizations, and significantly alter the quality of life of the dyad (family caregiver and the person being cared for). Intervening earlier in the care pathway would make it possible to avoid the aggravation of pathologies associated with MNCD and hospitalizations. The reorganization of activities imposed by the social distancing measures due to the pandemic has shown that e-health is a solution to maintain access to resources for people living with chronic conditions such as MNCD. We have been working since the beginning of the pandemic on the development of two complementary health applications for seniors and their dyads: the self-assessment questionnaire on frailty (CARE©) and the Evaluation et orientation SOcio-GÉRiatrique (ESOGER©) questionnaire : * CARE© is made by the dyad, allowing to identify a state of frailty and the risks related to it. It relies on the active participation of the user and is deployed in the form of an application. * ESOGER© is a standardized hetero-questionnaire filled out remotely, during a telephone call, by a community organization worker with the user and/or his/her caregiver. It is a tool for first contact, listening and accompanying a user, which makes it possible to determine whether the needs for care and services are being met, to prioritize the needs, to trigger the implementation of care and services, and to make the link with the organizations providing care and services. The objectives of this study are to examine the effects of CARE© combined with ESOGER© on the state of physical and mental frailty, loss of autonomy, quality of life, and consumption of health services and care resources in people living with a major neurocognitive disorder (MNCD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05571553
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Major Neurocognitive Disorder
Currently open trials in the same condition.
- NCT06701630 — Italian Adaptation and Validation of Functional and Behavioural Scales for Subjective Cognitive Decline, Mild Cognitive · recruiting
- NCT06631742 — Exergaming Revolution in Dementia · NA · recruiting
- NCT06615167 — Confirmatory Clinical Trial for Verifying the Efficacy and Safety of 'ALZGUARD' as a Digital Dementia Diagnostic Aid-Too · NA · recruiting
Other Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal trials
Trials by the same sponsor.
- NCT06605092 — Characterization of Emotional Response Profiles Triggered by a Digital Artwork of Musicalized Impressionist Paintings · NA · recruiting
- NCT06724757 — Survey for Caregivers Aged 50 and Over · enrolling by invitation
- NCT06296199 — Music, Virtual Reality for Patients in IUGM · NA · completed
- NCT05537688 — Identification of Graphic Markers of Neurocognitive Disorders (MG) · completed
- NCT05445453 — Museum Prescription by a Physician for a Visit to the MBAM · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05571553 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
- Last refreshed: 12 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05571553.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing